Journal
ONCOIMMUNOLOGY
Volume 10, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2021.1924500
Keywords
Amino-acid catabolizing enzyme; aryl-hydrocarbon receptor; T cell response; tumor microenvironment; immune escape
Categories
Funding
- Fondation BMS pour la Recherche en Immuno-Oncologie
- Institut National du Cancer INCA [2018-155]
Ask authors/readers for more resources
Although IL4I1 has emerged as a relevant therapeutic target for cancer, its precise role remains poorly understood. IL4I1 inhibits TCR signaling, modulates T cell differentiation, limits T cell proliferation, and shapes the tumor microenvironment in a way that impairs the antitumor immune response. The production of new IL4I1 metabolites may play a role in activating the aryl-hydrocarbon receptor (AHR), but the correlation between IL4I1 expression and AHR activation in human cancers is weak.
The amino-acid catabolizing enzyme Interleukin-4 induced gene 1 (IL4I1) remains poorly characterized despite it is emerging as a pertinent therapeutic target for cancer. IL4I1 is secreted in the synaptic cleft by antigen-presenting cells. It inhibits TCR signaling, modulates naive T cell differentiation and limits effector T cell proliferation. IL4I1 expression in tumors shapes the tumor microenvironment and impairs the antitumor cytotoxic T cell response, thereby facilitating cancer immune escape. Several mechanisms participate in these effects. Recent data suggest a role of new IL4I1 metabolites in activation of the aryl-hydrocarbon receptor (AHR). Here, we observe that expression of IL4I1 is poorly correlated with that of validated targets of AHR in human cancers. Moreover, dendritic cells do not upregulate AHR target genes in relation with IL4I1 expression in vivo. Finally, IL4I1 activity toward tryptophan leading to production of AHR-activating products is very low, and should be negligible when tryptophan-degrading enzymes of higher affinity compete for the substrate. We recently showed that IL4I1 expression by dendritic cells directly regulates immune synapse formation and modulates the repertoire and memory differentiation of responding CD8 T cells after viral infection. Thus, IL4I1 may restrain tumor control through regulating the priming of tumor-specific CD8 T cells, independently of AHR activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available